Stoke Therapeutics (STOK) Stock Forecast, Price Target & Predictions
STOK Stock Forecast
Stoke Therapeutics stock forecast is as follows: an average price target of $33.75 (represents a 133.24% upside from STOK’s last price of $14.47) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
STOK Price Target
The average price target for Stoke Therapeutics (STOK) is $33.75 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $58.00 to $20.00. This represents a potential 133.24% upside from STOK's last price of $14.47.
STOK Analyst Ratings
According to 6 Wall Street analysts, Stoke Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for STOK stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Stoke Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | Debjit Chattopadhyay | H.C. Wainwright | $35.00 | $15.32 | 128.46% | 141.88% |
| May 07, 2024 | Sumant Kulkami | Canaccord Genuity | $20.00 | $11.87 | 68.49% | 38.22% |
| Mar 26, 2024 | Joseph Stringer | Needham | $22.00 | $6.50 | 238.46% | 52.04% |
| Mar 26, 2024 | Sumant Kulkami | Canaccord Genuity | $21.00 | $10.92 | 92.31% | 45.13% |
| Nov 14, 2022 | - | Needham | $25.00 | $9.33 | 167.95% | 72.77% |
| Apr 26, 2021 | Judah Frommer | Credit Suisse | $58.00 | $32.50 | 78.46% | 300.83% |
The latest Stoke Therapeutics stock forecast, released on Sep 11, 2024 by Debjit Chattopadhyay from H.C. Wainwright, set a price target of $35.00, which represents a 128.46% increase from the stock price at the time of the forecast ($15.32), and a 141.88% increase from STOK last price ($14.47).
Stoke Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 4 |
| Avg Price Target | $35.00 | $35.00 | $24.50 |
| Last Closing Price | $14.47 | $14.47 | $14.47 |
| Upside/Downside | 141.88% | 141.88% | 69.32% |
In the current month, the average price target of Stoke Therapeutics stock is $35.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 141.88% increase as opposed to Stoke Therapeutics's last price of $14.47. This month's average price target is down 0.00% compared to last quarter, and up 42.86% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 11, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 28, 2024 | Needham | Buy | Buy | Hold |
| Jun 28, 2024 | Canaccord Genuity | Underperform | Underperform | Hold |
| May 07, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| May 06, 2024 | Wedbush | Buy | Buy | Hold |
| May 06, 2024 | Needham | Underperform | Underperform | Hold |
| Apr 04, 2024 | Needham | Underperform | Underperform | Hold |
| Apr 04, 2024 | Wedbush | Buy | Buy | Hold |
| Mar 26, 2024 | Needham | Buy | Buy | Hold |
Stoke Therapeutics's last stock rating was published by Cowen & Co. on Sep 11, 2024. The company gave STOK a "Buy" rating, the same as its previous rate.
Stoke Therapeutics Financial Forecast
Stoke Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $3.31M | $-2.48M | $5.15M | $3.27M | $2.90M | - | $3.00M |
| Avg Forecast | $1.50M | $1.50M | $1.50M | $1.50M | $3.27M | $3.64M | $3.70M | $3.26M | $3.66M | $3.64M | $3.44M | $3.00M | $2.86M | $2.72M | $2.64M | $50.00M |
| High Forecast | $1.50M | $1.50M | $1.50M | $1.50M | $3.27M | $4.21M | $3.70M | $3.26M | $4.95M | $3.64M | $3.44M | $3.00M | $2.86M | $2.72M | $2.64M | $60.33M |
| Low Forecast | $1.50M | $1.50M | $1.50M | $1.50M | $3.27M | $2.44M | $3.70M | $3.26M | $2.48M | $3.64M | $3.44M | $3.00M | $2.86M | $2.72M | $2.64M | $32.58M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.91% | -0.72% | 1.72% | 1.14% | 1.07% | - | 0.06% |
Stoke Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $3.66M, with a low forecast of $2.48M, and a high forecast of $4.95M. STOK's average Quarter revenue forecast represents a 10.75% increase compared to the company's last Quarter revenue of $3.31M (Sep 23).
Stoke Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-27.23M | $-33.26M | $-24.69M | $-27.18M | $-26.76M | - | $-24.55M |
| Avg Forecast | $300.00K | $300.00K | $300.00K | $300.00K | $653.04K | $728.04K | $740.54K | $652.05K | $732.70K | $728.57K | $688.89K | $600.00K | $572.53K | $544.44K | $528.12K | $-60.23M |
| High Forecast | $300.00K | $300.00K | $300.00K | $300.00K | $653.04K | $841.67K | $740.54K | $652.05K | $990.13K | $728.57K | $688.89K | $600.00K | $572.53K | $544.44K | $528.12K | $-48.18M |
| Low Forecast | $300.00K | $300.00K | $300.00K | $300.00K | $653.04K | $488.17K | $740.54K | $652.05K | $495.07K | $728.57K | $688.89K | $600.00K | $572.53K | $544.44K | $528.12K | $-72.27M |
| Surprise % | - | - | - | - | - | - | - | - | - | -37.38% | -48.28% | -41.15% | -47.46% | -49.15% | - | 0.41% |
undefined analysts predict STOK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Stoke Therapeutics's previous annual EBITDA (undefined) of $NaN.
Stoke Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | $-24.54M | $-30.65M | $-18.30M | $-22.05M | $-24.08M | - | $-24.40M |
| Avg Forecast | $-31.51M | $-32.07M | $-30.95M | $-31.51M | $-31.53M | $-29.95M | $-30.56M | $-34.01M | $-33.94M | $-35.27M | $-35.40M | $-39.09M | $-39.76M | $-38.16M | $-31.80M | $-61.10M |
| High Forecast | $-31.51M | $-32.07M | $-30.95M | $-31.51M | $-31.53M | $-26.68M | $-30.56M | $-34.01M | $-26.27M | $-35.27M | $-35.40M | $-39.09M | $-39.76M | $-38.16M | $-31.80M | $-48.88M |
| Low Forecast | $-31.51M | $-32.07M | $-30.95M | $-31.51M | $-31.53M | $-36.48M | $-30.56M | $-34.01M | $-38.86M | $-35.27M | $-35.40M | $-39.09M | $-39.76M | $-38.16M | $-31.80M | $-73.32M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.70% | 0.87% | 0.47% | 0.55% | 0.63% | - | 0.40% |
Stoke Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. STOK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Stoke Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | $10.27M | $10.23M | $10.21M | $9.38M | $9.94M | - | $9.49M |
| Avg Forecast | $3.18M | $3.18M | $3.18M | $3.18M | $6.91M | $7.71M | $7.84M | $6.90M | $7.76M | $7.71M | $7.29M | $6.35M | $6.06M | $5.76M | $5.59M | $23.51M |
| High Forecast | $3.18M | $3.18M | $3.18M | $3.18M | $6.91M | $8.91M | $7.84M | $6.90M | $10.48M | $7.71M | $7.29M | $6.35M | $6.06M | $5.76M | $5.59M | $28.22M |
| Low Forecast | $3.18M | $3.18M | $3.18M | $3.18M | $6.91M | $5.17M | $7.84M | $6.90M | $5.24M | $7.71M | $7.29M | $6.35M | $6.06M | $5.76M | $5.59M | $18.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.33% | 1.40% | 1.61% | 1.55% | 1.73% | - | 0.40% |
Stoke Therapeutics's average Quarter SG&A projection for Dec 23 is $7.76M, based on 6 Wall Street analysts, with a range of $5.24M to $10.48M. The forecast indicates a -24.48% fall compared to STOK last annual SG&A of $10.27M (Sep 23).
Stoke Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.55 | $-0.00 | $-0.43 | $-0.56 | $-0.61 | - | $-0.65 |
| Avg Forecast | $-0.56 | $-0.57 | $-0.56 | $-0.56 | $-0.57 | $-0.54 | $-0.55 | $-0.61 | $-0.61 | $-0.63 | $-0.63 | $-0.70 | $-0.71 | $-0.68 | $-0.69 | $0.36 |
| High Forecast | $-0.56 | $-0.57 | $-0.56 | $-0.56 | $-0.57 | $-0.48 | $-0.55 | $-0.61 | $-0.47 | $-0.63 | $-0.63 | $-0.70 | $-0.71 | $-0.68 | $-0.69 | $0.46 |
| Low Forecast | $-0.56 | $-0.57 | $-0.56 | $-0.56 | $-0.57 | $-0.65 | $-0.55 | $-0.61 | $-0.70 | $-0.63 | $-0.63 | $-0.70 | $-0.71 | $-0.68 | $-0.69 | $0.20 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.87% | 0.00% | 0.61% | 0.79% | 0.89% | - | -1.80% |
According to undefined Wall Street analysts, Stoke Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to STOK previous annual EPS of $NaN (undefined).
Stoke Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| ADAP | Adaptimmune Therapeutics | $1.11 | $2.83 | 154.95% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
STOK Forecast FAQ
Is Stoke Therapeutics a good buy?
Yes, according to 6 Wall Street analysts, Stoke Therapeutics (STOK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of STOK's total ratings.
What is STOK's price target?
Stoke Therapeutics (STOK) average price target is $33.75 with a range of $20 to $58, implying a 133.24% from its last price of $14.47. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Stoke Therapeutics stock go up soon?
According to Wall Street analysts' prediction for STOK stock, the company can go up by 133.24% (from the last price of $14.47 to the average price target of $33.75), up by 300.83% based on the highest stock price target, and up by 38.22% based on the lowest stock price target.
Can Stoke Therapeutics stock reach $20?
STOK's average twelve months analyst stock price target of $33.75 supports the claim that Stoke Therapeutics can reach $20 in the near future.
What is Stoke Therapeutics's current price target trend?
1 Wall Street analyst forecast a $35 price target for Stoke Therapeutics (STOK) this month, up 141.88% from its last price of $14.47. Compared to the last 3 and 12 months, the average price target increased by 141.88% and increased by 69.32%, respectively.
What are Stoke Therapeutics's analysts' financial forecasts?
Stoke Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $13.87M (high $14.44M, low $12.67M), average EBITDA is $2.77M (high $2.89M, low $2.53M), average net income is $-126M (high $-123M, low $-133M), average SG&A $29.36M (high $30.57M, low $26.82M), and average EPS is $-2.26 (high $-2.202, low $-2.378). STOK's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $6M (high $6M, low $6M), average EBITDA is $1.2M (high $1.2M, low $1.2M), average net income is $-126M (high $-126M, low $-126M), average SG&A $12.7M (high $12.7M, low $12.7M), and average EPS is $-2.26 (high $-2.26, low $-2.26).
Did the STOK's actual financial results beat the analysts' financial forecasts?
Based on Stoke Therapeutics's last annual report (Dec 2023), the company's revenue was $8.78M, which missed the average analysts forecast of $13.75M by -36.15%. Apple's EBITDA was $-115M, missing the average prediction of $2.75M by -4273.33%. The company's net income was $-105M, missing the average estimation of $-144M by -27.14%. Apple's SG&A was $41.32M, beating the average forecast of $29.12M by 41.93%. Lastly, the company's EPS was $-0.0024, missing the average prediction of $-2.577 by -99.91%. In terms of the last quarterly report (Sep 2023), Stoke Therapeutics's revenue was $3.31M, missing the average analysts' forecast of $3.64M by -9.19%. The company's EBITDA was $-27.234M, missing the average prediction of $728.57K by -3838.00%. Stoke Therapeutics's net income was $-24.542M, missing the average estimation of $-35.272M by -30.42%. The company's SG&A was $10.27M, beating the average forecast of $7.71M by 33.16%. Lastly, the company's EPS was $-0.55, missing the average prediction of $-0.632 by -13.04%